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Abstract
This study aimed to determine the risk factors for the development of drug-induced interstitial lung disease
(ILD) and poor-prognosis drug-induced ILD after erlotinib treatment. Patients were monitored for 120 days. The
risk factors were pre-existing ILD and the amount of residual normal lung (£ 50%) for drug-induced ILD and the
amount of residual normal lung (£ 50%) for poor-prognosis drug-induced ILD.
Introduction: Although interstitial lung disease (ILD) is a known serious adverse effect of epidermal growth factor
receptor tyrosine kinase inhibitors, the risk factors for its development are poorly deﬁned. To determine the risk factors
for the development of drug-induced ILD and poor-prognosis (fatal) drug-induced ILD after erlotinib treatment, we
assessed the baseline pulmonary status in patients with nonesmall cell lung cancer enrolled in a postmarketing
clinical study of erlotinib. Patients and Methods: In the present prospective cohort study, the baseline pulmonary
status of all patients was evaluated using conventional or high-resolution computed tomography. The patients were
monitored for the development of drug-induced ILD for 120 days after the start of treatment. All diagnoses of drug-
induced ILD were conﬁrmed by an independent ILD safety review committee. The risk factors were determined us-
ing logistic regression analysis. Results: A total of 645 patients were enrolled, of whom 627 were evaluable. The
committee conﬁrmed the diagnoses of drug-induced ILD in 19 patients, 6 of whom had fatal outcomes. Multivariate
logistic regression analysis revealed that pre-existing ILD and limited residual normal lung were signiﬁcant risk factors
for the development of drug-induced ILD. An additional multivariate logistic regression analysis revealed that limited
residual normal lung was a signiﬁcant risk factor for the development of poor-prognosis (fatal) drug-induced ILD.
Conclusion: Pre-existing ILD and the amount of residual normal lung ( 50%) were identiﬁed as risk factors for the
development of drug-induced ILD. The amount of residual normal lung ( 50%) was identiﬁed as a risk factor for the
development of poor-prognosis (fatal) drug-induced ILD.
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Interstitial lung diseases (ILDs) have many causes, including
drugs.1,2 These have been reported to include anticancer drugs,*This is an open access article under the CC BY-NC-SA license (http://
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raised particular concerns owing to numerous reports of drug-
induced ILD shortly after its launch. A rapid succession of fatal
cases occurred within a short period. Although drug-induced ILD is
thought to result from drug-induced airway epithelial (type II
alveolar epithelial) cytotoxicity and immunocyte activation, its
mechanism is poorly understood.3
The EGFR-TKI erlotinib (Chugai Pharmaceutical Co, Ltd,
Tokyo, Japan) is commonly used worldwide for its approved in-
dications in nonesmall cell lung cancer (NSCLC) and pancreatic
cancer.4,5 Although erlotinib is known to be associated with fewer
serious adverse reactions than other cytotoxic anticancer drugs, it
carries the same risk of ILD as geﬁtinib.6 A Japanese phase II clinical
study of erlotinib in patients with NSCLC reported a 2.2% to 6.5%
incidence of drug-induced ILD, with a mortality rate of 1.9%.7,8 A
Japanese postmarketing surveillance study of erlotinib in patients
with NSCLC analyzing the predictive factors for the development
of erlotinib-induced ILD identiﬁed the following risk factors for the
development or exacerbation of ILD (multivariate Cox proportional
hazard model of the relationship between drug-induced ILD and
baseline clinical characteristics): smoking history, ECOG perfor-
mance status 2 to 4, concurrent or previous ILD, and concurrent or
previous lung infection.6
Diagnostic imaging is an important tool for differentiating drug-
induced ILD from the primary disease or infection and selecting the
treatment for drug-induced ILD at its onset. Baseline diagnostic
imaging is also important for determining the pretreatment pul-
monary status to aid in the prevention of EGFR-TKIeinduced
ILD.
A study conducted to identify the risk factors for the develop-
ment of geﬁtinib-induced ILD reported that pre-existing ILD was a
risk factor for the development of drug-induced ILD. Additionally,
pre-existing ILD, limited residual normal lung, and extensive areas
of lung restriction were risk factors for the development of poor-
prognosis drug-induced ILD.9 To our knowledge, however, no
further study has been reported. We, therefore, assessed the baseline
pulmonary status using computed tomography (CT) to determine
the risk factors for the development of drug-induced ILD and poor-
prognosis (fatal) drug-induced ILD after erlotinib treatment in a
cohort of patients enrolled in a postmarketing clinical study of
erlotinib (nested case control study; JO21661 study10) designed to
identify the predictive biomarkers for the development of drug-
induced ILD.
Patients and Methods
The present study used data from patients enrolled in a multi-
center postmarketing clinical study of erlotinib (150 mg/d orally
once daily; dose reduction and interruption permitted) conducted
from April 17, 2008 to January 14, 2010. The institutional review
board of each participating institution had approved the study,
which had been conducted in accordance with Good Clinical
Practice and the Declaration of Helsinki.
Patient Population
The present study included patients determined by the investi-
gator to meet all of the following cohort inclusion criteria: (1) ex-
pected to enroll in the postmarketing surveillance study of erlotinib;
(2) histologically or cytologically conﬁrmed NSCLC; and (3)voluntary written informed consent provided to participate in the
study. The following were the cohort exclusion criteria: (1)
chemotherapy naive (except for patients with recurrence after
postoperative adjuvant therapy); (2) clear radiologic evidence sug-
gestive of concurrent or previous ILD; (3) expected to participate in
another clinical trial during the study period; and (4) found un-
suitable for participation in the study by the investigator. Thus, 645
patients were included in the cohort. The CT scans were analyzed
for 627 of these 645 patients. Of the 645 patients, 18 were excluded
as ineligible, including 9 patients who did not receive erlotinib and
9 without conventional or high-resolution CT data for evaluation of
the baseline pulmonary status.
Evaluation of ILD Occurring After Erlotinib Treatment
The patients were monitored for the development of erlotinib-
induced ILD for 120 days after the start of treatment. The data
from the patients with investigator-diagnosed drug-induced ILD
during the observation period were reviewed by an ILD safety re-
view committee consisting of a pulmonologist and diagnostic radi-
ologists. The patients conﬁrmed to have ILD by the review
committee were considered to have developed drug-induced ILD
for the purposes of the present study.
Evaluation of Baseline Pulmonary Status
The radiologic assessment was performed by an independent
radiology review committee of 4 chest radiologists. The radiologic
assessment consisted of evaluation of pretreatment conventional or
high-resolution CT scans. The reviewers were unaware of all clinical
information, except the CT scans, and used the same evaluation
form and criteria for all patients (Table 1). The CT scans were
evaluated for the following variables: severity of interstitial pneu-
monia, severity of emphysema, presence of lymphangitic carcino-
matosis, presence of healed tuberculosis, severity of radiation
pneumonitis, amount of residual normal lung, and extent of lung
restriction. The severity of interstitial pneumonia was classiﬁed as
mild (abnormalities in < 5% of bilateral lobes), moderate (abnor-
malities in 5%-20% of bilateral lower lobes), or severe (abnormal-
ities in > 20% of bilateral lower lobes). The severity of emphysema
was also classiﬁed as mild (emphysema in < 10% of the total lung),
moderate (emphysema in 10%-30% of the total lung), or severe
(emphysema in > 30% of the total lung).
To evaluate the reproducibility of the results of the assessment of
these variables, the radiologists were divided into 2 groups (group A
and group B) of 2 each. Each group evaluated the same 80 CT scans
and the same 40 CT scans at 2 different times to test the inter- and
intragroup concordance of the results of all variables, respectively.
Adverse Events
For the analysis of drug-induced ILD, the adverse event terms
recorded in the case report form were coded in accordance with the
“Medical Dictionary for Regulatory Activities” (MedDRA), version
11.0. The events were then summarized according to the MedDRA
preferred terms.
Statistical Analysis
Frequency tables and univariate logistic regression analysis were
conducted to evaluate the association between a single baselineClinical Lung Cancer November 2014 - 449
Table 1 Evaluation Criteria for Baseline Pulmonary Status (Computed Tomography Findings)
Finding Evaluation Criteria Category for Severity
Pre-existing ILD Nonsegmental ground glass opacities, consolidations, or reticular
opacities, honeycombing, traction bronchiectasis, and architectural
distortion
Mild: abnormalities involving <5% of bilateral lower lobes
Moderate: abnormalities involving 5%-20% of bilateral lower lobes
Severe: abnormalities involving >20% of bilateral lower lobes
Emphysema Localized areas of decreased attenuation, with cysts Mild: emphysema involving <10% of total lung
Moderate: emphysema involving 10%-30% of total lung
Severe: emphysema involving >30% of total lung
Lymphangitic carcinomatosis Interlobular septal and bronchovascular interstitium thickening
(with occasional nodular thickening), hilar and mediastinal nodal
enlargement, and pleural effusion, with nodular opaciﬁcation
indicative of primary tumor or hematogenous metastasis in some
cases
NA
Radiation pneumonitis Nonsegmental ground glass opacities, consolidations, or reticular
opacities; dense consolidations with volume reduction;
abnormalities conﬁned to irradiated ﬁeld
Mild: nonsegmental ground glass opacities or consolidations
only, or nonsegmental ground glass opacities or consolidations
with ﬁbrotic lesions
Severe: well-deﬁned ﬁbrotic lesions only
Healed tuberculosis Calciﬁed nodules or lymph nodes, upper lobe scarring, volume
reduction, and traction bronchiectasis
NA
Baseline residual normal lung Percentage of normally functioning lung should be measured
and assessed (areas of lung with any of the following lesions
should be considered to be functioning abnormally and excluded
from measurement): adhesions (particularly postoperatively),
ﬁbrotic lesions, emphysema or emphysematous bullae, previous
pulmonary tuberculosis, all other pulmonary lesions
NA
Extent of lung restriction Proportion of lung with adhesions from surgery or previous
pulmonary tuberculosis or with restricted respiratory movement
from cancer inﬁltration
NA
Abbreviations: ILD ¼ interstitial lung disease; NA ¼ not assessed for severity.
Risk Factors for Interstitial Lung Disease
450 -pulmonary variable and drug-induced ILD or poor-prognosis (fatal)
drug-induced ILD. Multivariate logistic regression was then
performed to identify the risk factors for drug-induced ILD or poor-
prognosis (fatal) drug-induced ILD among the baseline pulmonary
variables. To obtain the ﬁnal model, the stepwise method was used,
with a 2-sided 5% signiﬁcance level. To ensure estimate accuracy,
variables with  3 categories were reclassiﬁed into 2 major cate-
gories. If all patients were classiﬁed into 1 category despite reclas-
siﬁcation, the variable was excluded from the logistic regression
analysis. In the analysis of the inter- and intragroup concordance, in
addition to the agreement rate, the weighted or simple kappa co-
efﬁcient was calculated for the evaluable variables (excluding thoseTable 2 Results of Analysis of Inter- and Intragroup Reproducibility
Variable
Intergroup Agreement R
(%)/Kappa Coefﬁcien
Pre-existing ILD (all categories) 75.0/0.37
Pre-existing ILD (absent or present) 82.5/0.53
Emphysema (all categories) 72.5/0.60
Emphysema (absent or present) 83.8/0.68
Lymphangitic carcinomatosis (absent or present) 91.3/0.58
Healed tuberculosis (absent or present) 93.8/NC
Radiation pneumonitis (absent or present) 92.5/0.71
Amount of residual normal lung (all categories) 47.5/0.60a
Amount of residual normal lung (50%/>50%) 87.5/0.43
Extent of lung restriction (all categories) 71.3/0.67a
Extent of lung restriction (0%/10%) 85.0/0.63
Abbreviations: ILD ¼ interstitial lung disease; NC ¼ not calculated.
aWeighted kappa coefﬁcient.
Clinical Lung Cancer November 2014with small counts in some cells of the contingency table). For
variables with  3 category levels, concordance was determined by
both all categories and the reclassiﬁed categories. All analyses were
conducted using statistical analysis systems, version 9.2 (SAS
Institute, Cary, NC).
Results
Incidence of Drug-Induced ILD
A diagnosis of drug-induced ILD was conﬁrmed by the ILD
safety review committee in 19 (3.0%) of the 627 patients, with 6
fatal cases. The drug-induced ILD events that occurred in these 19
patients consisted of interstitial pneumonia in 15 patients (78.9%),ate
t
Intragroup A Agreement
Rate (%)/Kappa Coefﬁcient
Intragroup B Agreement
Rate (%)/Kappa Coefﬁcient
82.5/0.62 67.5/0.41
85.0/0.67 80.0/0.58
82.5/0.72 80.0/0.71
95.0/0.90 89.7/0.79
90.0/0.44 95.0/0.77
100.0/e 92.5/NC
95.0/0.83 95.0/0.64
57.5/068a 65.0/0.76a
90.0/0.61 95.0/0.77
75.0/0.60a 67.5/0.54a
85.0/0.58 77.5/0.52
Table 3 Baseline Pulmonary Status in Patients With and
Without Development of Drug-Induced ILD
Variable
Patients With
Development
of Drug-Induced
ILD (n [ 19)
Patients Without
Development
of Drug-Induced
ILD (n [ 608)
Total
(n [ 627)
Pre-existing ILD
Severe 0 (0.0) 2 (0.3) 2 (0.3)
Moderate 1 (5.3) 6 (1.0) 7 (1.1)
Mild 4 (21.1) 34 (5.6) 38 (6.1)
Absent 14 (73.7) 566 (93.1) 580 (92.5)
Emphysema
Severe 0 (0.0) 24 (3.9) 24 (3.8)
Moderate 3 (15.8) 72 (11.8) 75 (12.0)
Mild 5 (26.3) 102 (16.8) 107 (17.1)
Absent 11 (57.9) 409 (67.3) 420 (67.0)
Indeterminate 0 (0.0) 1 (0.2) 1 (0.2)
Lymphangitic
carcinomatosis
Present 5 (26.3) 102 (16.8) 107 (17.1)
Absent 14 (73.7) 505 (83.1) 519 (82.8)
Indeterminate 0 (0.0) 1 (0.2) 1 (0.2)
Healed tuberculosis
Present 1 (5.3) 21 (3.5) 22 (3.5)
Absent 18 (94.7) 587 (96.5) 605 (96.5)
Radiation
pneumonitis
Severe 1 (5.3) 70 (11.5) 71 (11.3)
Mild 0 (0.0) 7 (1.2) 7 (1.1)
Absent 18 (94.7) 529 (87.0) 547 (87.2)
Indeterminate 0 (0.0) 2 (0.3) 2 (0.3)
Residual normal
lung amount
>50% 12 (63.2) 549 (90.3) 561 (89.5)
50% 7 (36.8) 59 (9.7) 66 (10.5)
Extent of lung
restriction
0% 11 (57.9) 419 (68.9) 430 (68.6)
10% 8 (42.1) 188 (30.9) 196 (31.3)
Data presented as n (%).
Abbreviation: ILD ¼ interstitial lung disease.
Takeshi Johkoh et alpneumonitis in 2 (10.5%), and lung disorder and radiation pneu-
monitis in 1 patient (5.3%) each, using the MedDRA preferred
term. The worst grade of drug-induced ILD according to the
Common Terminology Criteria for Adverse Events, version 3.0, was
grade 2 and grade 5 in 6 patients each (31.6%), grade 1 in 4 patients
(21.1%), grade 3 in 2 patients (10.5%), and grade 4 in 1 patient
(5.3%). Drug-induced ILD developed within 28 days after the start
of treatment in most patients, occurring within 14 days after the
start of treatment in 8 patients and between 15 and 28 days after the
start of treatment in 5 patients. Erlotinib was discontinued and
necessary treatment provided to all patients who developed drug-
induced ILD.
Inter- and Intragroup Concordance of Radiology
Assessment
The intergroup and intragroup concordance is summarized in
Table 2. The intergroup agreement rates were  80% and the
kappa coefﬁcients were  0.4 when the variables with  3 cate-
gories were reclassiﬁed into 2 categories. The intergroup agreement
rates were still  70% and the kappa coefﬁcients were  0.35 when
the categories were not collapsed and the variables with a large
number of categories, including the amount of residual normal
lung, extent of lung restriction, and severity of interstitial pneu-
monia, were excluded.
The intragroup agreement rates were  75% and the kappa
coefﬁcients were  0.4 when the variables were reclassiﬁed. The
intragroup agreement rates were still  70% and the kappa co-
efﬁcients were  0.5 when the categories were not collapsed and the
variables with a large number of categories were excluded.
Baseline Pulmonary Status and Association With
Development of Drug-induced ILD
The baseline pulmonary status in patients with and without the
development of drug-induced ILD is listed in Table 3. The variables
present in  10% of the patients who developed drug-induced ILD
included pre-existing ILD, the amount of residual normal lung, and
the extent of lung restriction.
The results of univariate logistic regression analysis using the
7 candidate risk factors as the explanatory variable and the results of
the multivariate logistic regression analysis using the signiﬁcant
factors to determine the association between each variable and the
development of drug-induced ILD are listed in Table 4.
According to the univariate logistic regression analysis, the pres-
ence of pre-existing ILD (odds ratio, 4.814; 95% CI, 1.654-14.007)
and limited residual normal lung (odds ratio, 5.429; 95% CI,
2.058-14.321) were signiﬁcant factors for the development of drug-
induced ILD.
The ﬁnal model from the multivariate logistic regression analysis
consisted of the presence of pre-existing ILD (odds ratio, 4.039;
95% CI, 1.344-12.140) and limited residual normal lung (odds
ratio, 4.801; 95% CI, 1.786-12.907). These were signiﬁcant risk
factors for the development of drug-induced ILD.
Baseline Pulmonary Status and Association With
Development of Poor-prognosis (Fatal) Drug-induced ILD
The baseline pulmonary status in patients with and without the
development of poor-prognosis (fatal) drug-induced ILD is listed inTable 5. The amount of residual normal lung was the only variable
that was present 10% more in patients with development of
poor-prognosis (fatal) drug-induced ILD than those without.
The results of univariate logistic regression analysis evaluating the
association between the development of poor-prognosis (fatal) drug-
induced ILD and the results of multivariate logistic regression
analysis are listed in Table 6.
From the univariate logistic regression analysis, only the amount
of residual normal lung was a signiﬁcant factor (odds ratio, 8.857;
95% CI, 1.750-44.817). The ﬁnal model from the multivariate
logistic regression analysis revealed that the amount of residual
normal lung was a signiﬁcant risk factor for the development of
poor-prognosis (fatal) drug-induced ILD.Clinical Lung Cancer November 2014 - 451
Table 4 Logistic Regression Analysis for Development of Drug-Induced ILD
Analysis
Reference Category/Evaluation
Category OR 95% CI
Univariate analysis
Pre-existing ILD Absent/present 4.814 1.654-14.007
Emphysema Absent/present 1.502 0.595-3.794
Lymphangitic carcinomatosis Absent/present 1.768 0.623-5.018
Healed tuberculosis Absent/present 1.553 0.198-12.186
Radiation pneumonitis Absent/present 0.382 0.050-2.900
Amount of residual normal lung >50%/50% 5.429 2.058-14.321
Extent of lung restriction 0%/10% 1.621 0.642-4.095
Final model from multivariate analysis
Pre-existing ILD Absent/present 4.039 1.344-12.140
Amount of residual normal lung >50%/50% 4.801 1.786-12.907
Abbreviations: CI ¼ conﬁdence interval; ILD ¼ interstitial lung disease; OR ¼ odds ratio.
Risk Factors for Interstitial Lung Disease
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Drug-induced ILD is an infrequent, but potentially fatal, adverse
effect of many drugs. Early diagnosis and treatment are, therefore,
essential.11,12 Drug-induced ILD has been diagnosed through a
comprehensive evaluation of drug treatment history, clinical
symptoms, and laboratory, imaging, and pathology results. Diag-
nostic imaging is important primarily to provide an understanding
of the baseline pulmonary status and radiographic pattern after
onset, determining the severity and extent of the lesions, and
assessing the treatment response. In the present study, we radio-
graphically assessed the baseline pulmonary status to prospectively
identify the risk factors related to drug-induced ILD in patients
already enrolled in a postmarketing clinical study (nested case
control study; JO21661 study) of erlotinib.
Although only a small number of drug-induced ILD or fatal
drug-induced ILD cases occurred, the risk factors for the develop-
ment of drug-induced ILD and poor-prognosis (fatal) drug-induced
ILD were identiﬁed through multivariate logistic regression analysis
to take the correlations among the variables into consideration. The
analysis revealed that pre-existing ILD and the amount of residual
normal lung were signiﬁcant risk factors for the development of
drug-induced ILD. The latter variable was also a risk factor for the
development of poor-prognosis (fatal) drug-induced ILD. The
amount of residual normal lung was not evaluated in the post-
marketing surveillance study of erlotinib6; thus, it was identiﬁed as a
new risk factor for the development of drug-induced ILD in the
present study. These results are similar to those reported in a pre-
vious study conducted to identify the risk factors for the develop-
ment of drug-induced ILD associated with the EGFR-TKI
geﬁtinib.9
Although “clear radiologic evidence suggestive of concurrent or
previous ILD” was established as an exclusion criterion in the pre-
sent study, 47 of the 627 patients (7.5%) were found to have
radiologic evidence of pre-existing ILD according to the assessment
criteria established by the study’s independent review committee of
diagnostic radiologists. This was mainly because the independent
review committee consisted of specialists of diffuse ILD who could
thus identify the evidence of previous ILD more particularly thanClinical Lung Cancer November 2014could the participating physicians. The type of drug-induced ILD
was classiﬁed as “other (unknown)” for most of the patients. These
ﬁndings demonstrate the clinical difﬁculty of discerning pre-existing
ILD. The results of the present study conﬁrming that pre-existing
ILD is a risk factor for drug-induced ILD and thus point to a
need for an improved clinical ability to diagnose pre-existing ILD to
prevent and avoid drug-induced ILD. The inter-radiologist agree-
ment rates were 45% to 95% and the kappa coefﬁcients were 0.35
to 0.7, demonstrating great enough accuracy for the diagnostic
criteria used in the present study. Additional improvement of the
accuracy through new ﬁndings, however, is an important future
task.
Only 5 of the 47 patients with pre-existing ILD developed drug-
induced ILD after erlotinib treatment. The drug-induced ILD was
radiologically mild in 4 and moderate in 1 of these patients. The
type of drug-induced ILD was classiﬁed as “other” in all 5 patients
(emphysematous ﬁbrosis in 1 patient, subpleural linear opaciﬁcation
in 1 patient, unclassiﬁable in 1 patient, undifferentiated in 1 patient,
and “other” in 1 patient). No conclusions could be drawn regarding
the radiologic features of pre-existing ILD or the baseline radiologic
features of patients developing drug-induced ILD.
Known to be prone to concurrent ILD, patients with lung cancer
experience a greater incidence of concurrent usual interstitial
pneumonia and other chronic interstitial pneumonias than generally
reported in patients with other diseases. Concurrent ILD was re-
ported in 63 (2.3%) of 2723 patients with lung cancer by Park
et al13 and in 36 (3.9%) of 931 patients with unresectable lung
cancer by Chiyo et al.14 Conﬁrmation of the increased risk of drug-
induced ILD in patients with pre-existing ILD in the present study
emphasizes the particular importance of a careful evaluation of the
baseline pulmonary status before erlotinib treatment in patients
with lung cancer owing to the frequency of concurrent latent ILD.
Although the mechanism is still poorly understood, drug-induced
ILD has been thought to be caused primarily by drug-induced
airway epithelial (type II alveolar epithelial) cytotoxicity and
immunocyte activation, modulated by a number of host and envi-
ronmental factors. Transforming growth factor-a and its receptor
EGFR are abundantly expressed in type 2 epithelial cells in patients
Table 5 Baseline Pulmonary Status of Patients With and
Without Development of Poor-Prognosis Drug-
Induced ILD
Variable
Patients With
Development of
Poor-Prognosis
Drug-Induced
ILD (n [ 6)
Patients Without
Development of
Poor-Prognosis
Drug-Induced
ILD (n [ 621)
Total
(n [ 627)
Pre-existing ILD
Severe 0 (0.0) 2 (0.3) 2 (0.3)
Moderate 0 (0.0) 7 (1.1) 7 (1.1)
Mild 0 (0.0) 38 (6.1) 38 (6.1)
Absent 6 (100.0) 574 (92.4) 580 (92.5)
Emphysema
Severe 0 (0.0) 24 (3.9) 24 (3.8)
Moderate 0 (0.0) 75 (12.1) 75 (12.0)
Mild 2 (33.3) 105 (16.9) 107 (17.1)
Absent 4 (66.7) 416 (67.0) 420 (67.0)
Indeterminate 0 (0.0) 1 (0.2) 1 (0.2)
Lymphangitic
carcinomatosis
Present 1 (16.7) 106 (17.1) 107 (17.1)
Absent 5 (83.3) 514 (82.8) 519 (82.8)
Indeterminate 0 (0.0) 1 (0.2) 1 (0.2)
Healed tuberculosis
Present 0 (0.0) 22 (3.5) 22 (3.5)
Absent 6 (100.0) 599 (96.5) 605 (96.5)
Radiation
pneumonitis
Severe 0 (0.0) 71 (11.4) 71 (11.3)
Mild 0 (0.0) 7 (1.1) 7 (1.1)
Absent 6 (100.0) 541 (87.1) 547 (87.2)
Indeterminate 0 (0.0) 2 (0.3) 2 (0.3)
Residual normal
lung amount
>50% 3 (50.0) 558 (89.9) 561 (89.5)
50% 3 (50.0) 63 (10.1) 66 (10.5)
Extent of lung
restriction
0% 4 (66.7) 426 (68.6) 430 (68.6)
10% 2 (33.3) 194 (31.2) 196 (31.3)
Data presented as n (%).
Abbreviation: ILD ¼ interstitial lung disease.
Takeshi Johkoh et alwith idiopathic pulmonary ﬁbrosis, indicating that they play a role
in the repair of damaged epithelial cells. EGFR is involved in the
growth of type 2 epithelial cells, and reduced EGFR function has
been reported to be an aggravating factor for the development of
pulmonary ﬁbrosis.15 The exacerbation of lung disorders by EGFR-
TKIs can therefore be assumed to result from an impaired epithelial
repair mechanism owing to inhibition of the growth of type 2
epithelial cells.
The EGFR-TKI geﬁtinib, with a similar mechanism of action to
erlotinib, has been reported to augment bleomycin (BLM)-induced
lung injury and pulmonary ﬁbrosis in mice.16 However, erlotinibwas not reported to induce or exacerbate lung injury in BLM-
treated rats.17 In addition, the relevance of animal models to hu-
man pulmonary ﬁbrosis is currently unclear, and the mechanism of
acute exacerbation of pre-existing ILD by EGFR-TKIs is still poorly
understood.
In the present study, 7 of the 19 patients who developed drug-
induced ILD had  50% residual normal lung at baseline.
Although the amount of residual normal lung was a signiﬁcant
risk factor for the development of ILD and poor-prognosis (fatal)
drug-induced ILD, 5 of these 7 patients had concurrent disease,
such as emphysema, lymphangitic carcinomatosis, or radiation
pneumonitis.
Drug-induced ILD is generally known to occur in normal lungs.
However, the extensive areas of epithelial regeneration in the
diseased remaining lungs of patients with limited normal lung will
increase susceptibility to ILD. When lung disease does develop, it
occurs in normal lungs, compromising gas exchange and leading to
a poor prognosis.
A previous study conducted to identify the risk factors for the
development of drug-induced ILD associated with geﬁtinib reported
that extensive areas of lung restriction was a risk factor for a poor
prognosis for patients developing drug-induced ILD. The present
study did not identify extensive areas of lung restriction as a risk
factor for either drug-induced ILD or poor-prognosis (fatal) drug-
induced ILD. Although this might have been because of differ-
ences in method (eg, study design and analysis method) between the
geﬁtinib study and the present study, the exact reason is unknown.
Although several studies to date have reported on the predictive
factors for ILD, it is currently difﬁcult to prevent EGFR-TKIein-
duced ILD. However, a recent report by Namba et al18 described
the mechanism of the development of geﬁtinib-dependent pulmo-
nary ﬁbrosis and its inhibition by the gastrointestinal ulcer drug
teprenone in mice, suggesting a new treatment modality.
The present study had the following limitations. First, the study
was not designed with sufﬁcient power to detect radiographic risk
factors for drug-induced ILD. Second, the clinical characteristics
were not included in the analyses. Third, the serum concentration
of erlotinib was not measured. Fourth, the baseline pulmonary
evaluations included radiologic ﬁndings only, without inclusion of
the pathologic assessment. Finally, the multicenter nature of the
study resulted in the use of different imaging parameters and
equipment by the different centers.
The present prospective cohort study evaluating the relationship
between baseline pulmonary status and drug-induced ILD has
suggested that the presence of pre-existing ILD and the amount of
residual normal lung are strongly associated with the development
of drug-induced ILD after treatment with EGFR-TKIs. These re-
sults have shown that CT assessment of baseline pulmonary status
to determine the risk of drug-induced ILD can provide vital in-
formation in deciding a course of treatment.
Conclusion
The present study identiﬁed the following radiographic variables
as risk factors (high-risk categories) for the development of drug-
induced ILD. Pre-existing ILD and the amount of residual
normal lung ( 50%) were identiﬁed as risk factors for the devel-
opment of drug-induced ILD. The amount of residual normal lungClinical Lung Cancer November 2014 - 453
Table 6 Logistic Regression Analysis for Poor-Prognosis Drug-Induced ILD
Analysis
Reference Category/Evaluation
Category OR 95% CI
Univariate analysis
Emphysema Absent/present 1.020 0.185-5.613
Lymphangitic carcinomatosis Absent/present 0.970 0.112-8.386
Amount of residual normal lung >50%/50% 8.857 1.750-44.817
Extent of lung restriction 0%/10% 1.098 0.199-6.045
Final model from multivariate analysis
Amount of residual normal lung >50%/50% 8.810 1.741-44.577
Abbreviations: ILD ¼ interstitial lung disease; OR ¼ odds ratio.
Risk Factors for Interstitial Lung Disease
454 -( 50%) was also identiﬁed as a risk factor for the development of
poor-prognosis (fatal) drug-induced ILD.
Clinical Practice Points
 Our study found radiographic variables that are risk factors
(high-risk categories) for the development of drug-induced ILD.
 Pre-existing ILD and the amount of residual normal lung
( 50%) were risk factors for the development of drug-induced
ILD.
 The amount of residual normal lung ( 50%) was also a risk
factor for the development of poor-prognosis (fatal) drug-
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